Cancers,
Год журнала:
2023,
Номер
15(10), С. 2758 - 2758
Опубликована: Май 14, 2023
Cancer
metastasis
is
a
significant
challenge
in
cancer
treatment,
and
most
existing
drugs
are
designed
to
inhibit
tumor
growth
but
often
ineffective
treating
metastatic
cancer,
which
the
leading
cause
of
cancer-related
deaths.
Resveratrol,
polyphenol
found
grapes,
berries,
peanuts,
has
shown
potential
preclinical
studies
as
an
anticancer
agent
suppress
metastasis.
However,
despite
positive
results
studies,
little
progress
been
made
clinical
trials.
To
develop
resveratrol
effective
agent,
it
crucial
understand
its
cellular
processes
signaling
pathways
This
review
article
evaluates
current
state
future
development
strategies
enhance
potency
against
within
therapeutic
dose.
In
addition,
we
critically
evaluate
animal
models
used
for
discuss
novel
techniques
accelerate
translation
from
bench
bedside.
The
appropriate
selection
vital
determining
whether
can
be
further
developed
antimetastatic
drug
therapy.
Nature Reviews Clinical Oncology,
Год журнала:
2018,
Номер
16(3), С. 185 - 204
Опубликована: Дек. 4, 2018
Abstract
Most
cancer-related
deaths
are
a
result
of
metastasis,
and
thus
the
importance
this
process
as
target
therapy
cannot
be
understated.
By
asking
‘how
can
we
effectively
treat
cancer?’,
do
not
capture
complexity
disease
encompassing
>200
different
cancer
types
—
many
consisting
multiple
subtypes
with
considerable
intratumoural
heterogeneity,
which
in
variable
responses
to
specific
therapy.
Moreover,
have
much
less
information
on
pathophysiological
characteristics
metastases
than
is
available
for
primary
tumour.
disseminated
tumour
cells
that
arrive
distant
tissues,
surrounded
by
unfamiliar
foreign
microenvironment,
likely
die;
however,
those
survive
generate
metastatic
tumours
markedly
biology
from
To
metastasis
effectively,
must
inhibit
fundamental
processes
develop
preclinical
clinical
strategies
rely
responses.
address
crucial
issue,
Cancer
Research
UK
Therapeutics
CRC
Australia
formed
Metastasis
Working
Group
representatives
not-for-profit,
academic,
government,
industry
regulatory
bodies
order
recommendations
how
tackle
challenges
associated
treating
(micro)metastatic
disease.
Herein,
describe
identified
well
proposed
approaches
discovering
developing
anticancer
agents
designed
specifically
prevent
or
delay
outgrowth
cancer.
Journal of Translational Medicine,
Год журнала:
2018,
Номер
16(1)
Опубликована: Март 20, 2018
Immunotherapy
has
matured
into
standard
treatment
for
several
cancers,
but
much
remains
to
be
done
extend
the
reach
of
its
effectiveness
particularly
cancers
that
are
resistant
within
each
indication.
This
review
proposes
nutrition
can
affect
and
potentially
enhance
immune
response
against
cancer.
The
general
mechanisms
link
nutritional
principles
function
may
influence
anticancer
immunotherapy
examined.
represents
also
premise
a
research
project
aimed
at
identifying
best
diet
enhancement
tumours
(D.I.E.T
project).
Particular
attention
is
turned
gut
microbiota
impact
composition
on
system.
Also,
dietary
patterns
effecting
discussed
including
value
adhering
healthy
diets
such
as
Mediterranean,
Veg,
Japanese,
or
Microbiota-regulating
diet,
very
low
ketogenic
which
have
been
demonstrated
lower
risk
developing
reduce
mortality
associated
with
them.
Finally,
supplements,
omega-3
polyphenols,
potential
approaches
could
benefit
lifestyle
habits
in
context
immunotherapy.
Trends in Immunology,
Год журнала:
2019,
Номер
40(4), С. 328 - 344
Опубликована: Март 7, 2019
Methylation
of
DNA
at
CpG
sites
is
the
most
common
and
stable
epigenetic
changes
in
cancer.
Hypermethylation
acts
to
limit
immune
checkpoint
blockade
immunotherapy
by
inhibiting
endogenous
interferon
responses
needed
for
recognition
cancer
cells.
By
contrast,
global
hypomethylation
results
expression
programmed
death
ligand
1
(PD-L1)
inhibitory
cytokines,
accompanied
epithelial-mesenchymal
that
can
contribute
immunosuppression.
The
drivers
these
contrasting
methylation
states
are
not
well
understood.
also
plays
a
key
role
cytotoxic
T
cell
'exhaustion'
associated
with
tumor
progression.
We
present
an
updated
exploratory
analysis
how
may
define
patient
subgroups
be
targeted
develop
tailored
treatment
combinations
help
improve
outcomes.
Genes,
Год журнала:
2019,
Номер
10(2), С. 172 - 172
Опубликована: Фев. 23, 2019
A
DNA
sequence
is
the
hard
copy
of
human
genome
and
it
a
driving
force
in
determining
physiological
processes
an
organism.
Concurrently,
chemical
modification
its
related
histone
proteins
dynamically
involved
regulating
diseases,
which
overall
constitutes
epigenome
network.
Among
various
forms
epigenetic
modifications,
methylation
at
C-5
position
cytosine
cytosine⁻guanine
(CpG)
dinucleotide
one
most
well
studied
modifications.
methyltransferases
(DNMTs)
are
family
enzymes
generating
maintaining
CpG
across
genome.
In
mammalian
systems,
performed
by
DNMT1
DNMT3s
(DNMT3A
3B).
predominantly
maintenance
during
cell
division,
while
establishing
de
novo
both
embryonic
somatic
cells.
general,
all
DNMTs
require
accessory
proteins,
such
as
ubiquitin-like
containing
plant
homeodomain
(PHD)
really
interesting
new
gene
(RING)
finger
domain
1
(UHRF1)
or
DNMT3-like
(DNMT3L),
for
their
biological
function.
This
review
mainly
focuses
on
role
DNMT3B
isoforms
methylation,
especially
with
respect
to
protein.
Cancer Letters,
Год журнала:
2024,
Номер
591, С. 216894 - 216894
Опубликована: Апрель 16, 2024
This
comprehensive
review
delves
into
the
pivotal
role
of
tumor
microenvironment
(TME)
in
cancer
metastasis
and
therapeutic
response,
offering
fresh
insights
intricate
interplay
between
cells
their
surrounding
milieu.
The
TME,
a
dynamic
ecosystem
comprising
diverse
cellular
acellular
elements,
not
only
fosters
progression
but
also
profoundly
affects
efficacy
conventional
emerging
therapies.
Through
nuanced
exploration,
this
illuminates
multifaceted
nature
elucidating
its
capacity
to
engender
drug
resistance
via
mechanisms
such
as
hypoxia,
immune
evasion,
establishment
physical
barriers
delivery.
Moreover,
it
investigates
innovative
approaches
aimed
at
targeting
including
stromal
reprogramming,
modulation,
extracellular
matrix
(ECM)-targeting
agents,
personalized
medicine
strategies,
highlighting
potential
augment
treatment
outcomes.
Furthermore,
critically
evaluates
challenges
posed
by
complexity
heterogeneity
which
contribute
variable
responses
potentially
unintended
consequences.
underscores
need
identify
robust
biomarkers
advance
predictive
models
anticipate
outcomes,
well
advocate
for
combination
therapies
that
address
multiple
facets
TME.
Finally,
emphasizes
necessity
an
interdisciplinary
approach
integration
cutting-edge
technologies
unravel
intricacies
thereby
facilitating
development
more
effective,
adaptable,
treatments.
By
providing
critical
current
state
TME
research
implications
future
oncology,
highlights
evolving
landscape
field.
